J&J: bladder cancer study halted

(CercleFinance.com) - J&J announces that the SunRISe-2 study in patients with muscle-invasive bladder cancer (MVC) without radical cystectomy has been discontinued, having failed to show superiority over chemotherapy and radiotherapy.


Despite this, we remain confident in TAR-200 as a transformative therapy for bladder cancer, thanks in particular to the promising data from the SunRISe-4 study, J&J says.

The pharma group plans to submit an FDA application for TAR-200 as monotherapy in non-muscle-invasive bladder cancer in early 2025, while continuing the SunRISe-3 and SunRISe-5 studies.

It adds that it has renewed its confidence in the TARIS platform, which is said to present a potential of over $5bn.


Copyright (c) 2024 CercleFinance.com. All rights reserved.